Tectonic CEO granted 69,250 options at $29.92

Tectonic Therapeutic’s chief executive officer received a new multi-year stock option award with time-based vesting tied to continued service.

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. (TECX) reported that Chief Executive Officer and director Alise Reicin received a grant of employee stock options covering 69,250 shares of common stock on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036.

According to the vesting terms, 1/8 of the options vest on September 3, 2026, with the remaining shares vesting in 42 equal monthly installments beginning on October 3, 2026, subject to her continued service with the company. No Rule 10b5-1 trading plan is reported in connection with this award.

Insider Trade Summary

Grant/Award: 69,250 shares

Grant/Award 1 txn

Insider REICIN ALISE

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1	69,250	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 69,250 contracts (Direct)

Footnotes (1)

1. F1. 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Option shares granted: 69,250 options Underlying common shares: 69,250 shares Exercise price: $29.92 per share +3 more

6 metrics

Option shares granted 69,250 options Employee stock options granted to CEO on September 3, 2026

Underlying common shares 69,250 shares Common stock underlying the employee stock options

Exercise price $29.92 per share Exercise price for the CEO’s employee stock options

Expiration date September 2, 2036 Option term end date for the CEO’s employee stock options

Initial vesting portion 1/8 of option shares Vesting cliff on September 3, 2026

Remaining vesting installments 42 monthly installments Equal monthly vesting beginning October 3, 2026, subject to continued service

Key Terms

Employee Stock Option, vest, equal monthly installments

3 terms

Employee Stock Option financial

"Employee Stock Option (Right to Buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

vest financial

"1/8th of the shares subject to the option vest on September 3, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

equal monthly installments financial

"remaining shares subject to the option vesting in the following 42 equal monthly installments"

FAQ

What equity award did TECX grant to its CEO Alise Reicin?

Tectonic Therapeutic granted Alise Reicin an employee stock option covering 69,250 shares of common stock on September 3, 2026, as reported in the Form 4, with an exercise price of $29.92 per share and expiration on September 2, 2036.

What is the exercise price of the new stock options reported for TECX’s CEO?

The employee stock options granted to TECX’s CEO have an exercise price of $29.92 per share. These options relate to 69,250 shares of common stock and were awarded on September 3, 2026, with an expiration date of September 2, 2036.

How do the TECX CEO’s new stock options vest?

The options vest over time: 1/8 of the shares vest on September 3, 2026, and the remaining shares vest in 42 equal monthly installments starting on October 3, 2026, subject to Alise Reicin’s continued service with Tectonic Therapeutic.

How many TECX option shares will the CEO hold after this reported transaction?

Following this grant, Alise Reicin is reported as holding 69,250 stock options directly. These options give her the right to purchase up to 69,250 shares of Tectonic Therapeutic common stock at the stated exercise price, subject to the vesting schedule.

Are the TECX CEO’s reported option grants under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is affirmed for this transaction. The reported activity is a grant of employee stock options, not a market purchase or sale under a pre-arranged trading plan.

Do the new TECX options for the CEO involve an immediate cash payment?

No immediate cash payment is reported. The options provide the right to buy 69,250 shares at $29.92 per share in the future, subject to vesting. The grant is reported at a price of $0.00 per option, which is typical for employee stock option awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:45 PM Accepted by SEC EDGAR 09/08/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REICIN ALISE

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$29.92	09/03/2026		A		69,250		(1)	09/02/2036	Common Stock	69,250	$0	69,250	D

Explanation of Responses:

1. 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)